Treatment Innovations
Innovations in cancer treatment are transforming patient care by introducing more precise, effective, and less invasive therapies. Immunotherapy, including checkpoint inhibitors and CAR-T cell therapy, has revolutionized cancer care by harnessing the immune system to target and destroy cancer cells.
New breakthrough in cancer research offers hope for early detection
Scientists have developed a novel method for early cancer detection, potentially increasing survival rates through earlier interventions.
Revolutionary’ move in curing cancer on the horizon
A biotech company’s CEO discusses upcoming revolutionary approaches in cancer treatment, highlighting the role of new technologies.
Pfizer announces successful trial results for colorectal cancer drug
Pfizer’s latest clinical trial shows promising results for its new colorectal cancer drug, marking a significant advancement in treatment options.
Key enzyme identified as potential target for cancer immunotherapy
Scientists from A*STAR Genome Institute of Singapore (A*STAR GIS) have uncovered that a key enzyme—P4HA1 prolyl hydroxylase, is strongly induced in CD8+ T cells in solid cancer, the primary immune cells involved in combating cancer. P4HA1 causes disruptions in energy production within the cells, which leads to weaker immune cells that are less able to fight cancer and form long-lasting anti-cancer immunity, highlighting P4HA1 as a promising target for treating solid tumors.
FDA Approves Amgen Treatment For Pretreated Colorectal Cancer With Certain Mutation – Amgen (NASDAQ:AMGN) – Benzinga
Amgen’s Lumakras treatment, combined with Vectibix, is FDA-approved for KRAS G12C-mutated colorectal cancer.
Biomarker algorithm for Barrett’s esophagus and esophageal cancer developed
By studying biomarkers known to be involved in gastrointestinal cancers, researchers at the Johns Hopkins Kimmel Cancer Center and the Johns Hopkins University School of Medicine have developed a biomarker algorithm that, when combined with a noninvasive method to collect esophageal cells for study, could give clinicians insight into which patients [SJMM1] have esophageal cancer or precancerous conditions such as Barrett’s esophagus (BE) or high-grade dysplasia. Typically, such determinations are made by endoscopy, an invasive procedure performed with patients under anesthesia.
New breast cancer treatment — and more headlines
Medical Watch Digest For Jan 22 New Breast Cancer Treatment A new drug candidate to help women with breast cancerThis drug works and it does not have the same side effects as current treatments acc…
Aspirin does not help prevent colon cancer recurrence
Aspirin does not help prevent colon cancer recurrence
Best-selling Apple product ‘has been exposing us to CANCER’
Apple has been accused of exposing users to cancer in a new lawsuit that claims one of tech giant’s best-selling products contain high levels of cancer-causing ‘forever chemicals.’
Tool gives more accurate estimates of recurrence risk and individual chemotherapy benefit in node-positive breast cancer
A new statistical tool that combines multiple clinical and pathologic factors with a patient’s 21-gene Oncotype DX Breast Recurrence Score result provides more accurate estimates about that patient’s breast cancer prognosis and their potential benefit from chemotherapy than either the Recurrence Score result or clinical factors alone.
Arrivent Biopharma targets gastrointestinal cancer with new facility in Delaware County
Arrivent Biopharma is establishing a new facility in Delaware County to advance treatments for gastrointestinal cancers, aiming to enhance research and development in the region.
Merck and Eisai announce positive Phase 3 results for Keytruda and Lenvima combination
The combination of Keytruda and Lenvima met primary endpoints in a Phase 3 trial, showing significant improvement in overall survival for patients with advanced cancers.
KU, Children’s Mercy, Saint Luke’s focus on precision medicine – Kansas City Business Journal
Using a patient’s genomics to craft a treatment plan shows great promise for cancer and rare disease patients, and these three KC-area providers are dialing up their offerings.
The #1 Cancer-Fighting Food To Eat Because It ‘Slows Tumor Growth’ And Blocks Its Ability To Spread, Health Expert Reveals | SHEfinds
Cancer is a complex disease characterized by the uncontrolled growth of abnormal cells in the body.
BeiGene wins US nod for Tevimbra label expansion (BGNE:NASDAQ) | Seeking Alpha
BeiGene (BGNE) has received U.S. FDA approval for its cancer drug Tevimbra in combination with chemotherapy for certain gastric carcinoma. Read more here.
Glass of milk a day cuts bowel cancer risk – study – BBC News
Dark leafy greens, bread and non-dairy milks containing calcium were also found to offer protection.
Chimerix files FDA application for brain cancer treatment – Triangle Business Journal
The Durham company is seeking a fast track to regulatory approval for its brain cancer treatment.
FDA sets priority review date for Verastem Oncology’s new ovarian cancer drug – Boston Business Journal
The FDA is aiming to make a decision about the treatment before the end of June.
Francis Medical raises $80 million for device that treats prostate cancer – Minneapolis / St. Paul Business Journal
The Maple Grove-based company, spun off from the former NxThera Inc., plans to use proceeds from the round to fund a clinical trial of its Vanquish device in the treatment of prostate cancer.
Amgen Lumakras cleared for colorectal cancer (AMGN:NASDAQ) | Seeking Alpha
Amgen (AMGN) stock in focus as U.S. approval for its lung cancer drug expands for metastatic colorectal cancer. Read more here.
FDA Approves Datroway for Pretreated Advanced Breast Cancer
In trial, datopotamab deruxtecan increased progression-free survival by 2 months
Protein CD74 can predict immunotherapy response in bowel cancer, independent of subtype
Bowel cancer is the fourth most common cancer in the UK, and the second most common cause of cancer death. The disease falls into two types: one where proteins that repair errors in DNA are missing or deficient (the deficient subtype), and one where this machinery is intact (the proficient subtype).
Press release for research from the 2024 ASTRO Annual Meeting
IMRT and proton therapy offer equally high quality of life and tumor control for people with prostate cancer – American Society for Radiation Oncology (ASTRO)
Nanoparticle Therapy Offers New Hope for Prostate Cancer Patients | University of Virginia School of Engineering and Applied Science
Prostate cancer is the second leading cause of cancer death among American men.
